News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Exelixis, Inc. (EXEL) Release: Cabozantinib And Cobimetinib To Be Featured In Ten Presentations At 2014 American Society of Clinical Oncology Annual Meeting



5/15/2014 9:34:27 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Exelixis, Inc. (NASDAQ: EXEL) today announced that cabozantinib and cobimetinib will be the subject of ten presentations at the upcoming 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting, which will be held May 30 to June 3, 2014 in Chicago, Illinois, is expected to draw more than 25,000 oncology professionals from around the world.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES